SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community members intensely debate Donald Trump's recent State of the Union address, fueling highly polarized opinions regarding his economic claims and the political implications for his media company.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amid robust community discussion around its ANKTIVA cancer treatment and intense short squeeze speculation, fueled by ongoing international regulatory progress and anticipation of further corporate developments. Investors are highly optimistic about the company's scientific advancements and its potential global market impact.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following an earnings beat and robust revenue growth, with investors actively debating its high valuation and moderating same-store sales against its aggressive new restaurant expansion and perceived competitive edge over rivals like Chipotle.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is trending with multiple bullish analyst ratings and high price targets for its lead candidate AVTX-009, which has completed enrollment in its Phase 2 trial for hidradenitis suppurativa. The community is actively discussing the stock's significant upside potential in the competitive autoimmune disease market.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors digest reported earnings, which showed revenue growth but wider losses, alongside a significant workforce reduction aimed at improving profitability. The community is actively debating the company's substantial cash burn and the ongoing leadership situation, balanced by discussion around increasing production efficiency and future EV model launches.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as it reports an 18th consecutive "beat and raise" quarter, touting an AI disruptor edge and projecting positive GAAP net income for the upcoming fiscal year. The community is actively debating if its proprietary data and AI integration can sustain growth, with many anticipating significant upside despite broader software sector concerns.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as reports emerge of Stripe's interest in acquiring the payments company, sparking widespread community discussion around its perceived undervaluation and the potential for a bidding war, given its extensive user base and strong cash flow.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is actively trending as discussions focus on its substantial multi-year AI chip deal with AMD, potentially granting Meta a 10% stake, and new reports of a stablecoin payments launch, fueling community debate about the company's significant capital expenditure for AI and its future strategic direction.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is actively discussed as investors eagerly await potential administrative action or announcements regarding its release from conservatorship and uplisting to a major exchange, following recent comments from key officials indicating the company's readiness for an IPO. The community is split between frustration over perceived delays and price dips, and strong optimism among long-term holders who believe in the significant intrinsic value of the Government-Sponsored Enterprise.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is at the center of attention following record-breaking battery swaps during the Lunar New Year, with the community actively debating whether this milestone validates its unique battery-as-a-service model as a path to profitability or if persistent sales challenges and dilution concerns will continue to weigh on the EV maker.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>TeraWulf is expected to report fourth-quarter revenue of $44.1 million, according to data from fiscal.ai. The company in the same quarter last year reported a revenue of $35 million.&nbsp;</li><li>A user on Stocktwits predicted that the stock will cross $30 post its earnings because of WULF’s growth in energy and data centers.&nbsp;</li><li>TeraWulf has been pivoting aggressively from Bitcoin mining toward high-performance computing and AI data center hosting.&nbsp;</li></ul>Shares of TeraWulf rallied 10% on Tuesday as investors eagerly await its quarterly earnings that are expected to come this week.&nbsp;At the time of writing, stock was up 13% at $17.74.&nbsp;<h2 class="st-heading-2">What Is Retail Thinking?</h2>Retail sentiment around WULF trended in ‘neutral’ territory amid ‘low’ message volume.&nbsp;One bullish user said that if bitcoin is believed to be at $150,000 levels, then WULF stock can reach $60 by the end of 2026.&nbsp;<stembedurl>https://stocktwits.com/zingman/message/645741240</stembedurl>Another bullish user said that they wished to have 100 times more WULF shares than they currently own.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/645735377</stembedurl>Yet&nbsp;another user predicted that the stock will cross $30 post its earnings because of WULF’s growth in energy and data centers.&nbsp;<stembedurl>https://stocktwits.com/jam324/message/645735138</stembedurl><h2 class="st-heading-2">Q4 Earnings Preview</h2>TeraWulf is expected to report fourth-quarter revenue of $44.1 million, according to data from fiscal.ai. The company in the same quarter last year reported a revenue of $35 million.&nbsp;The company is also expected to post a higher loss of $0.14 per share in the fourth quarter compared to a loss per share of $0.08 in the same quarter last year.&nbsp;<h2 class="st-heading-2">Company’s Move To AI/HPC</h2>TeraWulf has been&nbsp; pivoting aggressively from Bitcoin mining toward high-performance computing (HPC) and AI data center hosting. Earlier in the month, it announced that it is expanding its digital and power infrastructure portfolio.The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.WULF stock has rallied more than 300%&nbsp;over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Terawulf Stock Is Up 10% But Retail Still Sees More Than 250% Upside: Here’s Why

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai. 

Equity

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai. 


Should Schwab U.S. Small-Cap ETF (SCHA) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Wealth-management stocks slid on Tuesday after tech platform Altruist introduced an AI-powered tax planning tool.</li><li>Wurster said the selloff left him “disappointed and surprised” because he believes that AI would strengthen advisers’ capabilities.</li><li>Schwab is well-positioned to benefit from AI due to its scale and extensive data, Wurster added.</li></ul>Charles Schwab (SCHW) CEO Rick Wurster pushed back against growing concerns that artificial intelligence could disrupt the wealth management industry, arguing instead that the technology will enhance adviser productivity.Wurster emphasized that AI should be viewed as a supportive tool rather than a replacement for human expertise, according to a Bloomberg interview on Wednesday. “With the power of AI, not only are we reaching those clients we have a relationship with, we are able to help a whole new group of clients,” Wurst said.His comments came after a selloff that dragged down shares of several wealth-management firms following the launch of Altruist’s AI-powered tax planning tool on Tuesday.<a href="https://stocktwits.com/symbol/SCHW">SCHW stock</a> was down 3% in morning trade after closing over 7% lower in the previous session.<h2 class="st-heading-2">Altruist’s AI Tool Leads To Selloff</h2>Wealth-management stocks slid on Tuesday after tech platform Altruist introduced an AI-powered tax planning tool within its Hazel platform, raising concerns about pressure on traditional advisory services. Shares of Raymond James Financial fell over 8%, while Stifel Financial declined around 4% on Tuesday.The tool analyzes client financial data to create personalized tax strategies, aiming to improve outcomes and efficiency. Altruist added that strict zero data-retention agreements ensure customer information is not stored or used to train AI models.<h2 class="st-heading-2">Wurster Says He Is Disappointed And Surprised By Recent Selloff</h2>Wurster said the decline in the brokerage’s shares left him “disappointed and surprised” because he believes that artificial intelligence would strengthen advisers’ capabilities rather than replace them.“The market is missing that we are a natural winner in the AI space because of all of the advantages we have — because of our size, our scale, our data,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment shifted to ‘bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SCHW_jpg_af0628c78b.webp" alt="SCHW.jpg">However, some users expressed concerns about the company’s future amid the “AI onslaught”.<stembedurl>https://stocktwits.com/Free43ver/message/644650446</stembedurl><stembedurl>https://stocktwits.com/Mahaperrotta/message/644618898</stembedurl>SCHW stock has shed over 3% so far in 2026.was up 1.6% in pre-market trading after closing over 7% lower in the previous session.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/khc-stock-slumps-weak-q4-results-pauses-separation/cZb6X4CR4qY">Kraft Heinz Pauses Separation Plan Amid Weak Q4 Print – KHC Stock Slumps 7% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Charles Schwab company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Charles Schwab CEO Reportedly Explains Why AI Won’t Disrupt Wealth Management Industry: ‘We Are Able To Help A Whole New Group Of Clients’

CEO Rick Wurster said that AI should be viewed as a supportive tool rather than a replacement for human expertise, according to an interview with Bloomberg on Wednesday.

Will the Ongoing Market Rally Continue in 2026? ETFs in Focus

S&P 500 momentum and retail inflows set the stage for a potential 2026 rally, with ETFs offering ways to ride the bullish trend.

More Fed Rate Cuts in 2026? ETFs to Play the Opportunities

Softer inflation and dovish signals point to more 2026 rate cuts. These ETFs can help investors ride potential gains.

ETFs to Benefit From Rate Cut Bets and Upbeat Forecasts

ETFs to watch as Wall Street turns upbeat, with bullish forecasts putting the S&P 500 on track for 8,000 by 2026.

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

ETFs to Ride the Small-Cap Comeback Wave 

Rate cut hopes and investor rotation beyond tech are fueling renewed momentum in small-cap stocks, with the Russell 2000 surging in August.

Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$30.65
Prev Close	$30.36
Open	$30.37
Dividend Yield	N/A
50-Day Moving Average	$29.94
Beta	N/A
Avg. Volume	3.27M
PE Ratio	N/A

52-Week High	$31.25
52-Week Low	$20.04
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

SCHA
Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SCHA News

SCHASchwab Strategic Trust - Schwab U.S. Small-Cap ETF